RedHill: Positive UK Regulatory Meeting

 RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA^®) for Oncology Support

UK MHRA scientific advice meeting deems RHB-102 (BEKINDA^®) data supportive of submission for approval for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV)

RHB-102 UK Marketing Authorisation Application (MAA) submission planned for 2H/23

If approved for marketing by the MHRA, RHB-102 could become the first oral 24hr extended-release 5-HT3 antiemetic drug in the UK indicated for the treatment of CINV/RINV

https://www.biospace.com/article/releases/redhill-biopharma-ltd-announces-redhill-s-rhb-102-positive-mhra-meeting-and-maa-plan/